NCT04742842 - The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2023

Conditions

SARS-CoV2 COVID-19

Interventions

BIOLOGICAL

COVIGEN C19 0.8 mg ID or Placebo ID

2 doses of COVIGEN C19 0.8 mg ID or Placebo ID will be given at Day 1 and Day 29.

BIOLOGICAL

COVIGEN C19 2.0 mg IM or Placebo IM

2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.

BIOLOGICAL

COVIGEN C19 4.0 mg IM or Placebo IM

2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.

BIOLOGICAL

COVIGEN C20 1.0mg vaccine ID

COVIGEN C20 1.0mg ID vaccine will be given at Day 1

Trial Locations (3)

Scientia Clinical Research, Randwick

Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide

Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth